<DOC>
	<DOCNO>NCT00382512</DOCNO>
	<brief_summary>This Phase I , randomize , placebo-controlled , single blind , parallel group , single-center study design evaluate immune response administration 12 weekly SC dose 1.0 mg/kg efalizumab subject moderate plaque psoriasis .</brief_summary>
	<brief_title>A Study Evaluate Effects Efalizumab Immune Responses Subjects With Moderate Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed informed consent Plaque psoriasis cover 8 % 15 % total BSA Diagnosis plaque psoriasis least 6 month Body weight ≤140 kg 18 65 year old For woman childbearing potential men may father child , use acceptable method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study ( follow method contraception acceptable : condom ; abstinence ; oral , implantable injectable contraceptive sexual partner ; IUD , female condom , diaphragm spermicide , cervical cap ; sterile sexual partner ) Willingness hold sun exposure reasonably constant avoid use tan booth UV light source study History tetanus vaccination Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis History severe allergic anaphylactic reaction humanize monoclonal antibody fusion protein contain Ig Fc region Clinically significant psoriasis exacerbation screen time enrollment History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History opportunistic infection ( e.g. , systemic fungal infection , parasite ) Seropositivity human immunodeficiency virus ( HIV ) Pregnancy lactation White blood cell ( WBC ) count &lt; 4000/uL &gt; 14,000/uL Seropositivity hepatitis B C virus Hepatic enzymes ≥3 time upper limit normal Tetanus pneumococcal vaccination 6 month prior start study ( Treatment Day 0 ) failure complete primary series tetanus immunization Known hypersensitivity reaction tetanus diphtheria toxoid Known hypersensitivity administer vaccination component History active tuberculosis ( TB ) currently undergo treatment TB Positive purify protein derivative ( PPD ) ( tuberculin ) test screen ( define CDC Guidelines , see Appendix C test assessment criterion list highrisk group ) Presence malignancy within past 5 year , include lymphoproliferative disorder Treatment efalizumab ( antiCD11a ) within last 12 month Previous administration &lt; phi &gt; X174 Diagnosis hepatic cirrhosis , regardless cause severity Serum creatinine ≥2 time upper limit normal Hospital admission cardiac disease , stroke , pulmonary disease within last year History substance abuse within last 5 year judge Principal Investigator Any medical condition , judgment investigator , would jeopardize subject 's safety follow exposure study drug Systemic therapy psoriasis ( Screening Day 28 FU Day 98 ) Systemic immunosuppressive drug indication ( Screening Day 28 FU Day 98 ) Live virus bacteria vaccine protocol specify ( Screening Day 14 Treatment Day 84 ) Other vaccine allergy desensitization ( must schedule least 14 day prior Treatment Day 0 FU Day 98 ) Other experimental drug treatment ( within 90 day five halflives , whichever longer , prior Treatment Day 0 FU Day 98 ) &lt; beta &gt; Blockers , angiotensinconverting enzyme ( ACE ) inhibitor , quinidine , antimalarial drug , lithium ( clinically indicate , medication allow dosage hold constant Screening Day 28 Treatment Day 84 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Moderate Plaque Psoriasis</keyword>
</DOC>